Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Servier Pharmaceuticals LLC
Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
May 23, 2026
Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)
May 18, 2026
Servier’s New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research
November 14, 2025
Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
November 5, 2025
Servier’s VORANIGO® (vorasidenib) Receives Prestigious 2025 Prix Galien USA Award
November 2, 2025